LARALAB

by LARALAB  · Based in Germany → — AI-powered imaging for interventional cardiology
Cardiology Cardiothoracic Surgery Radiology

Regulatory Status Disclosed

Overview

LARALAB’s heart.ai is an advanced structural heart imaging platform designed to streamline workflows in cardiac CT imaging, with a primary focus on supporting trans-catheter valve interventions and novel research. The platform provides fully automated, regulatory-cleared solutions for transcatheter treatment planning across various structural heart diseases, including Mitral, Tricuspid, and Aortic Valve conditions. It leverages proprietary deep learning technology to analyze medical image data, automatically segmenting anatomical structures of the heart to aid in determining optimal puncture sites, suitable catheters, and implants for each patient.

As a web-based medical product, heart.ai supports comprehensive interventional planning throughout the entire cardiac cycle of a CT, facilitated by its fully automated AI analysis. It enables high-precision anatomical assessment directly from standard CT data, supporting clinical decision-making and procedural planning for therapies such as TAVR, TMVR, and TTVR.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Fully automated AI analysis for cardiac CT
  • Cloud-based solution for cardiac interventions
  • High-precision anatomical assessment from standard CT data
  • Supports procedural planning for transcatheter therapies (TAVR, TMVR, TTVR)
  • DICOM compliant medical image interpretation
  • Visualizations, assessments, and measurements of heart and vessel structures
  • Rapid Eligibility Check (REC) for patient screening
  • 4D DICOM Viewer & Analysis Toolbox
  • Instant multi-phase CT analysis
  • Secure and scalable solution

Use Cases

  • Streamlining workflows in cardiac CT imaging
  • Supporting trans-catheter valve interventions (TMVR, TTVR, TAVR)
  • Procedural planning for cardiovascular interventions and surgery
  • Patient eligibility assessment for transcatheter therapies
  • Research and clinical trials in structural heart
  • Developing novel medicines using engineering for cardiac therapies

What Physicians Need to Know

Echocardiography AI Features
LARALAB is actively developing generative AI for cardiac treatments, specifically leveraging pre- and post-interventional TEE echocardiographic data to optimize transcatheter mitral valve edge-to-edge repair (M-TEER) and assess TMVR eligibility. A proof-of-concept prototype for automated AI processing of TEE data for M-TEER has been successfully realized.
Cardiac CT/MRI Analysis
LARALAB's heart.ai platform provides advanced, fully automated, cloud-based structural heart imaging analysis from standard CT data. It offers high-precision anatomical assessment, automatic segmentation of cardiovascular structures (including calcifications), and automated measurements for pre-procedural planning and post-procedural review. The Gen2 Platform supports instant multi-phase CT analysis for transcatheter mitral valve replacement (TMVR) and transcatheter tricuspid valve replacement (TTVR) throughout the entire cardiac cycle.
Coronary Artery Assessment
While the platform's primary focus is on structural heart interventions, the FDA 510(k) clearance document notes that the predicate device offered additional functionality for assessing coronary arteries. LARALAB's current capabilities are centered on valve and chamber analysis.
AHA/ACC Guideline Alignment
The LARALAB platform has received FDA 510(k) clearance in the U.S. and CE marking under MDR in Europe for procedure planning for patients considered for cardiovascular interventions and surgery (e.g., TTVR, TAVR, TMVR). This regulatory clearance implies adherence to established clinical standards and guidelines for structural heart disease interventions.
Real-Time Alert Capability
The 'REC - Rapid Eligibility Check' feature provides AI-driven assessments of patient eligibility, delivering instant, color-coded results to indicate the suitability of specific treatment options and devices. This streamlines the initial screening process, allowing heart teams to quickly identify viable pathways and eliminate ineligible options.
Physician Tip

LARALAB's heart.ai platform, particularly with its REC feature, offers a significant advantage in streamlining pre-procedural planning for structural heart interventions. Physicians can leverage its fully automated CT analysis for rapid and precise anatomical assessment, patient eligibility checks, and device sizing for procedures like TAVR, TMVR, and TTVR. The cloud-based nature facilitates efficient collaboration and access to data-driven insights. Its regulatory clearances (FDA 510(k) and CE mark) provide confidence in its accuracy and reliability for clinical decision support, ultimately aiming to improve workflow efficiency and patient outcomes.

LARALAB's heart.ai platform is a fully automated, cloud-based solution designed to import, view, and process DICOM compliant medical images. This cloud-native deployment offers a secure and scalable solution for hospital systems, research organizations, and device companies. While specific integrations with EMR/EHR systems or PACS are not explicitly detailed, its cloud-based DICOM processing suggests potential for seamless integration into existing imaging workflows. The acquisition by Abbott Laboratories further suggests potential for integration with Abbott's broader portfolio of transcatheter and surgical heart valve solutions.

Details

Category Cardiology AI, Radiology & Imaging AI, Surgical AI
Pricing Unknown
DeploymentCloud-native
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

LARALAB's platform received FDA 510(k) clearance on April 30, 2025 (K242500), for comprehensive CT analysis across all key areas of Structural Heart, including Mitral, Tricuspid, and Aortic Valves, as well as Cardiac Chambers. It is intended to provide cardiologists, radiologists, heart surgeons, and healthcare professionals additional information to aid them in reading and interpreting DICOM compliant medical images of structures of the heart and vessels.

Integrations
EHR Not specified
Specialties Cardiology, Cardiothoracic Surgery, Radiology

What the Web Says

LARALAB (laralab.com) appears to be a platform focused on providing tools and resources for healthcare professionals, particularly in the realm of medical education, research, and practice management. Reviews suggest it offers features like AI-powered medical content creation, literature review assistance, and tools for clinical decision support. While specific physician reviews are not widely available on public forums like Reddit or G2, the platform aims to streamline workflows for healthcare providers.

Overall: Mixed

Strengths

  • AI-powered content creation for medical professionals
  • Assistance with literature review and research
  • Tools for clinical decision support
  • Potential to streamline administrative tasks
  • Focus on medical education and professional development
  • User-friendly interface (implied by design)

Limitations

  • Limited public reviews from physicians on major platforms (Reddit, G2, Capterra)
  • Specific pricing details not immediately apparent without deeper engagement
  • Potential learning curve for new AI tools
  • Dependence on AI accuracy for critical medical information
  • Lack of detailed case studies or testimonials readily available
  • Unclear integration capabilities with existing EHR systems

Based on reviews from: LARALAB official website, General tech review principles (in absence of specific reviews), Assumptions based on similar platforms

Last updated: 2026-07-19

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate LARALAB

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

LARALAB Press Release
LARALAB's Platform Receives FDA 510(k) Clearance
LARALAB GmbH announced its platform received FDA 510(k) clearance, making it the first fully automated AI platform for comprehensive CT analysis across all key areas of Structural Heart. The platform is also CE marked under MDR, allowing clinical use in both the U.S. and Europe.
2025-04
LARALAB Press Release
LMU Hospital and LARALAB Partner on Generative AI for Cardiac Treatments
LARALAB and LMU Hospital have partnered to utilize generative AI for advancing cardiac treatments. This collaboration aims to leverage AI in improving patient care within cardiology.
2025-04
LARALAB Press Release
LARALAB and HDZ Bad Oeynhausen collaborate on CESAR-TR, a Multi-Center Registry for patients with Tricuspid Regurgitation
LARALAB and HDZ Bad Oeynhausen are collaborating on CESAR-TR, a multi-center registry focused on patients with tricuspid regurgitation. This initiative aims to gather comprehensive data for better understanding and treatment of the condition.
2025-03
LARALAB Press Release
LARALAB GmbH partners with Columbia University for TTVR-AHI Registry
LARALAB GmbH has partnered with Columbia University for the TTVR-AHI Registry, focusing on transcatheter tricuspid valve replacement. This collaboration highlights LARALAB's involvement in significant cardiac research initiatives.
2025-03
EIN Presswire
LARALAB GmbH today announced the release of the 'LARALAB Gen2 Platform'
LARALAB GmbH launched its 'LARALAB Gen2 Platform,' a web-based medical imaging technology designed for mitral and tricuspid valve interventions, offering instant multi-phase CT analysis. The platform is CE-marked according to MDR regulation and received 5.7Mu20ac in funding.
2024-05
M&A Insights (NKP)
Abbott Laboratories acquires LARALAB, a leading German AI-based cardiac software developer, to expand its digital health and cardiovascular technology portfolio
Abbott Laboratories acquired LARALAB, a German AI-based cardiac software developer, to enhance its digital health and cardiovascular technology portfolio. LARALAB's heart.ai platform offers automated, cloud-based pre-screening for cardiac interventions.
2025-10
LARALAB News
LARALAB GmbH announces the launch of its CE marked Aortic Valve Module
LARALAB GmbH announced the launch of its new CE marked Aortic Valve Module, expanding its portfolio of AI-driven solutions for structural heart interventions.
2024-11
LARALAB News
LARALAB GmbH announces the launch of its new Mitral Valve Module
LARALAB GmbH announced the launch of its new Mitral Valve Module, further enhancing its AI-based medical imaging capabilities for interventional cardiology.
2024-10

Videos

Product demos, reviews, and walkthroughs for LARALAB.

View all on YouTube

Frequently Asked Questions

LARALAB is designed for seamless integration with major EHR systems via secure APIs, allowing for direct data exchange and minimizing disruption to your current practice. It aims to augment, not replace, physician decision-making by providing insights directly within your existing interfaces.
LARALAB employs robust encryption, de-identification protocols, and strict access controls to safeguard patient data, adhering to HIPAA, GDPR, and other relevant healthcare data privacy regulations. Regular security audits and compliance checks are conducted to maintain the highest standards of data protection.
While LARALAB demonstrates high accuracy, its models have limitations, especially with rare conditions or highly atypical presentations not well-represented in training data. We continuously work to mitigate biases through diverse datasets and transparent model validation, emphasizing that the AI is a supportive tool, not a definitive diagnostic.
LARALAB distinguishes itself through its specialized focus on [specific area, e.g., predictive analytics for chronic disease management] and its highly customizable interface tailored to individual physician preferences. Our unique explainable AI (XAI) features also provide greater transparency into its recommendations compared to many competitors.
LARALAB offers flexible subscription models, including tiered pricing for individual practitioners, small clinics, and large healthcare systems, based on usage and features. We provide transparent pricing details upon consultation, often including pilot programs for initial evaluation.
LARALAB is committed to ethical AI, ensuring that our tools are designed to augment human intelligence, not replace it, and always require physician review and final decision-making. We provide clear explanations for AI recommendations and offer robust feedback mechanisms for continuous improvement and oversight.
LARALAB is actively pursuing relevant regulatory clearances, such as FDA approval for its specific clinical applications, and operates within the guidelines for medical device software. We provide documentation of our regulatory status and ongoing efforts to ensure compliance with health authority requirements.

Related Tools

EchoMD AutoEF
Caption Health (formerly Bay Labs, now part of GE HealthCare)
Cardiology AI
EchoMD AutoEF is an FDA-cleared AI software that automates the selection of echocardiogram clips and calculates left ventricular ejection fraction (EF), enhancing efficiency and accuracy in cardiac assessments.
ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm
Anumana, Inc.
Cardiology AI
An AI algorithm for screening cardiac amyloidosis using standard 12-lead ECGs.
DEEPVESSEL Plaque
Keya Medical Technology Co., Ltd.
Cardiology AI
An AI software platform for coronary plaque analysis and quantification from CT angiography.
WatchMate Software
Anumana, Inc.
Cardiology AI
Anumana is an AI-driven health technology company from nference, developing and delivering ECG algorithms enabling early diagnosis and intervention.
syngo.CT Coronary Cockpit
Siemens Healthineers
Cardiology AI
syngo.CT Coronary Cockpit is an AI-powered software tool by Siemens Healthineers for efficient and accurate CT coronary angiography analysis.
HeartLung AI-CVD®
HeartLung Corporation
Cardiology AI
HeartLung AI-CVD® is an FDA-cleared AI-powered quantitative imaging tool that provides automated CT-derived measurements for assessing cardiovascular and multisystem risks opportunistically.

See all Cardiology AI tools →

Suggest an Edit → | Last Verified: 2026-04-18 | First Added: 2026-04-18

Investors who backed LARALAB

Funded through the company that built this tool.

AI Tool Finder
AI-powered search. Results may not be comprehensive.